With world still in sore need of doses, Clover says its Covid-19 vaccine is 67% effective in Phase III

Josh Sullivan

With concerns about the Delta variant rising and much of the world still in desperate need of vaccine doses, a Chinese biotech announced Wednesday that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With world still in sore need of doses, Clover says its Covid-19 vaccine is 67% effective in Phase III

Josh Sullivan

Sign up to read this article for free.

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

With world still in sore need of dos­es, Clover says its Covid-19 vac­cine is 67% ef­fec­tive in Phase III

Josh Sullivan

Sign up to read this article for free.

more like this

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

With world still in sore need of doses, Clover says its Covid-19 vaccine is 67% effective in Phase III

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment